Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.

"Disclosure Dr Andrew Feber is an employee of Nonacus. Professor Sanjay Popat reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Bayer, personal fees from Beigene, personal fees from Blueprint, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from Daiichi Sankyo, personal fees from Guardant Health, personal fees from Incyte, personal fees from Janssen, personal fees from Lilly, personal fees from Merck Serono, personal fees from MSD, personal fees from Novartis, personal fees from Roche, personal fees from Takeda, personal fees from Pfizer, personal fees from Seattle Genetics, personal fees from Turning Point Therapeutics, personal fees from Xcovery, outside the submitted work. The authors report no other conflicts of interest in this work."